Impact of SLCO1B3 767G>C (rs60140950) polymorphism on paclitaxel response in Iraqi women with breast cancer

Abstract

Objective The aims of this study were to identify genetic polymorphism in solute carrier organic anion transporter 1B3 (SLCO1B3 767G>C (rs60140950)), and to examine the impacts of this polymorphism on the efficacy and safety of paclitaxel in Iraqi women with breast cancer (BC). Methods This cross-sectional observational study involved 150 women with BC who were administered paclitaxel. During the second week of paclitaxel therapy, these women were evaluated individually using a questionnaire to gather demographic information, such as their age and body mass index, as well as the likelihood and intensity of adverse effects of paclitaxel. Neutropenia levels and BC biomarkers were also evaluated. Result The wild-type genotype of the SLCO1B3 767G>C genetic polymorphism was identified in approximately 76% of BC cases. The mutant type (CC) and heterozygous type (GC) were identified in approximately 10% and 14% of cases, respectively. Among Iraqi women with BC carrying GG, GC, and CC genotypes, no significant differences were found in BC markers (cancer antigen 15-3 (CA 15-3) and carcinoembryonic antigen (CEA)) or paclitaxel-related side effects (neutropenia, oral mucositis, and peripheral neuropathy) at P > 0.05. Conclusion The distribution of the SLCO1B3 767G>C (rs60140950) genotype was high among Iraqi women with BC. No significant correlations were found between the SLCO1B3 767G>C genetic variant and changes in BC markers (CA 15-3 and CEA) or the incidence of early paclitaxel-related adverse effects.